Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer

Journal of Controlled Release

Volumn 146, Issue 2, 2010, Pages 212-218

  Cai, Shuang ^a   Thati, Sharadvi ^a   Bagby, Taryn R ^a   Diab, Hassam Mustafa ^a   Davies, Neal M ^b   Cohen, Mark S ^c   Forrest M Laird, M L ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Doxorubicin; Localized chemotherapy; Polymeric drug carrier

Indexed keywords

BIOPOLYMERS; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DIAGNOSIS; HISTOLOGY; MAMMALS; TARGETED DRUG DELIVERY; TISSUE; TOXICITY;

BREAST CANCER; DOXORUBICIN; EARLY BREAST CANCER; EARLY-STAGE BREAST CANCER; HUMAN BREAST CANCER; LYMPHATIC METASTASIS; PATIENT SURVIVALS; POLYMERIC DRUG CARRIERS;

DISEASES;

BIOPOLYMER; DOXORUBICIN; HYALURONIC ACID; NANOCARRIER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SURVIVAL RATE; SUSTAINED DRUG RELEASE; TUMOR XENOGRAFT;

EID: 77955413486     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.04.006     Document Type: Article

References (33)

1. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 2007, 49(5):330-352.
2. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., Shirao K., Okusaka T., Ueno H., Ikeda M., Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 2004, 91(10):1775-1781.
3. Rihova B., Strohalm J., Prausova J., Kubackova K., Jelinkova M., Rozprimova L., Sirova M., Plocova D., Etrych T., Subr V., Mrkvan T., Kovar M., Ulbrich K. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Control. Release 2003, 91(1-2):1-16.
4. Tolcher A.W., Sugarman S., Gelmon K.A., Cohen R., Saleh M., Isaacs C., Young L., Healey D., Onetto N., Slichenmyer W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 1999, 17(2):478-484.
5. National Cancer Institute: Breast cancer PDQ treatment, 2007, <> Access date 10/29/2009. http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional.
6. Querzoli P., Pedriali M., Rinaldi R., Lombardi A.R., Biganzoli E., Boracchi P., Ferretti S., Frasson C., Zanella C., Ghisellini S., Ambrogi F., Antolini L., Piantelli M., Iacobelli S., Marubini E., Alberti S., Nenci I. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin. Cancer Res. 2006, 12(22):6696-6701.
7. Boer M.d., Deurzen C.H.v., Dijck J.A.v., Borm G.F., Diest P.J.v., Adang E.M., Nortier J.W., Rutgers E.J., Seynaeve C., Menke-Pluymers M.B., Bult P., Tjan-Heijnen V.C. Micrometastases or isolated tumor cells and the outcome of breast cancer. N. Engl. J. Med. 2009, 361(7):653-663.
8. Fraser J.R., Laurent T.C. Turnover and metabolism of hyaluronan. Ciba Found. Symp. 1989, 143:41-53. discussion 53-49, 281-285.
9. Ahrens T., Assmann V., Fieber C., Termeer C., Herrlich P., Hofmann M., Simon J.C. CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J. Invest. Dermatol. 2001, 116(1):93-101.
10. Dietrich A., Tanczos E., Vanscheidt W., Schopf E., Simon J.C. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur. J. Cancer 1997, 33(6):926-930.
11. Gotte M., Yip G.W. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006, 66(21):10233-10237.
12. Misra S., Ghatak S., Toole B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem. 2005, 280(21):20310-20315.
13. Bartolazzi A., Peach R., Aruffo A., Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med. 1994, 180(1):53-66.
14. Asplund T., Heldin P. Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res. 1994, 54(16):4516-4523.
15. Sugahara S., Okuno S., Yano T., Hamana H., Inoue K. Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting. Biol. Pharm. Bull. 2001, 24(5):535-543.
16. Cera C., Palumbo M., Stefanelli S., Rassu M., Palu G. Water-soluble polysaccharide-anthracycline conjugates: biological activity. Anticancer Drug Des. 1992, 7(2):143-151.
17. Akima K., Ito H., Iwata Y., Matsuo K., Watari N., Yanagi M., Hagi H., Oshima K., Yagita A., Atomi Y., Tatekawa I. Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. J. Drug Target. 1996, 4(1):1-8.
18. Luo Y., Prestwich G.D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug. Chem. 1999, 10(5):755-763.
19. Bouhadir K.H., Alsberg E., Mooney D.J. Hydrogels for combination delivery of antineoplastic agents. Biomaterials 2001, 22(19):2625-2633.
20. Xu X., Sutak R., Richardson D.R. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. Mol. Pharmacol. 2008, 73(3):833-844.
21. Cai S., Xie Y., Bagby T., Cohen M.S., Forrest M.L. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J. Surg. Res. 2008, 147(2):247-252.
22. Al-Ghananeem A.H.M.A.M., Muammer Y.M., Balko J.M., Black E.P., Mourad W., Romond E. Intratumoral delivery of paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS PharmSciTech 2009, 10(2):410-417.
23. Peer R.M.D. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer 2004, 108(5):780-789.
24. Yadav A.K., Mishra P., Mishra A.K., Jain S., Agrawal G.P. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine 2007, 3(4):246-257.
25. Yadav A.K., Mishra P., Jain S., Mishra A.K., Agrawal G.P. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J. Drug Target. 2008, 16(6):464-478.
26. Lee H., Ahn C.H., Park T.G. Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin. Macromol. Biosci. 2009, 9(4):336-342.
27. Soloman R., Gabizon A.A. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin. Lymphoma Myeloma 2008, 8(1):21-32.
28. Lorusso D., Stefano A.D., Carone V., Fagotti A., Pisconti S., Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann. Oncol. 2007, 18(7):1159-1164.
29. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D.G., Tomczak P., Ackland S.P., Orlandi F., Mellars L., Alland L., Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15(3):440-449.
30. Wallemacq P.E., Capron A., Vanbinst R., Boeckmans E., Gillard J., Favier B. Permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions. Am. J. Health Syst. Pharm. 2006, 63(6):547-556.
31. Olson R.D., Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990, 4(13):3076-3086.
32. Quesada A.J., Nelius T., Yap R., Zaichuk T.A., Alfranca A., Filleur S., Volpert O.V., Redondo J.M. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ. 2005, 12(6):649-658.
33. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T.M., Corti A., Ponzoni M. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003, 63(21):7400-7409.